Evidence map›Paper›PMID 34107984›Full record

ArticleRadiation oncology (London, England)2021

Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China.

Xiao Chang, Wei Deng, Xin Wang, Zongmei Zhou, Jun Yang, Wenling Guo, Miaoling Liu, Xiaolu Qi, Ling Li, Kaixian Zhang and 31 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Radiation oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Contouring aid tools in radiotherapy. Smoothing: the false friend.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 15 institutions in 2 countries.

Xiao ChangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, People's Republic of China.
Wei DengDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, People's Republic of China.
Xin WangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, People's Republic of China.
Zongmei ZhouDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, People's Republic of China.
Jun YangDepartment of Oncology, First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, Weihui, 453100, Henan, People's Republic of China.
Wenling GuoDepartment of Oncology, First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, Weihui, 453100, Henan, People's Republic of China.
Miaoling LiuDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Xiaolu QiDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Ling LiDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, 277599, People's Republic of China.
Kaixian ZhangDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, 277599, People's Republic of China.
Min ZhangDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, 277599, People's Republic of China.
Yonggang ShiDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
Ke LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
Yidian ZhaoDepartment of Radiation Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang, 455000, People's Republic of China.
Huitao WangDepartment of Radiation Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang, 455000, People's Republic of China.
Zhilong YuDepartment of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Tongdao Road, Hohhot, 10050, Inner Mongolia, People's Republic of China.
Jihong ZhangDepartment of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Tongdao Road, Hohhot, 10050, Inner Mongolia, People's Republic of China.
Lihua WangDepartment of Radiation Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Tongdao Road, Hohhot, 10050, Inner Mongolia, People's Republic of China.
Xueying QiaoDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Chun HanDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Shuchai ZhuDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Ruohui ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Junqiang ChenDepartment of Radiation Oncology, Fujian Cancer Hospital/Fujian Medical University Cancer Hospital, Fuzhou, 350014, People's Republic of China.
Cairong HuDepartment of Radiation Oncology, Fujian Cancer Hospital/Fujian Medical University Cancer Hospital, Fuzhou, 350014, People's Republic of China.
Fuquan ZhangDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Dongcheng District, Beijing, People's Republic of China.
Xiaorong HouDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Dongcheng District, Beijing, People's Republic of China.
Qingsong PangDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Wencheng ZhangDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Gaofeng LiDepartment of Radiation Oncology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
Hailei LinDepartment of Radiation Oncology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
Xinchen SunDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Xiaolin GeDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Caihong LiDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Hong GeDepartment of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, People's Republic of China.
Dingjie LiDepartment of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, People's Republic of China.
Yadi WangDepartment of Radiation Oncology, The Seventh Medical Center of PLA General Hospital, Beijing, 100700, People's Republic of China.
Na LuDepartment of Radiation Oncology, The Seventh Medical Center of PLA General Hospital, Beijing, 100700, People's Republic of China.
Xianshu GaoDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, People's Republic of China.
Shangbin QinDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, People's Republic of China.
Yuan Tian *Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, People's Republic of China. yuan.tian@cicams.ac.cn.
Zefen Xiao *Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, People's Republic of China. xiaozefen@sina.com.ORCID http://orcid.org/0000-0003-0503-6814
Chinese Academy of Medical Sciences & Peking Union Medical College · CNHebei Medical University · CNInner Mongolia Medical University · CNJiangsu Province Hospital · CNTengzhou Central People's Hospital · CNAffiliated Hospital of Hebei University · CNBeijing Hospital · CNChinese PLA General Hospital · CNFirst Affiliated Hospital of Xinxiang Medical University · CNFujian Medical University · CNHenan Cancer Hospital · CNHenan University of Science and Technology · CNPeking University · CNTianjin Medical University Cancer Institute and Hospital · CNZhengzhou University · CN

Funding

the Beijing Hope Run Special Fund of Cancer Foundation of China LC2016L04
6 · The paper itself

Abstract

purposeTo investigate the interobserver variability (IOV) in target volume delineation of definitive radiotherapy for thoracic esophageal cancer (TEC) among cancer centers in China, and ultimately improve contouring consistency as much as possible to lay the foundation for multi-center prospective studies.

methodsSixteen cancer centers throughout China participated in this study. In Phase 1, three suitable cases with upper, middle, and lower TEC were chosen, and participants were asked to contour a group of gross tumor volume (GTV-T), nodal gross tumor volume (GTV-N) and clinical target volume (CTV) for each case based on their routine experience. In Phase 2, the same clinicians were instructed to follow a contouring protocol to re-contour another group of target volume. The variation of the target volume was analyzed and quantified using dice similarity coefficient (DSC).

resultsSixteen clinicians provided routine volumes, whereas ten provided both routine and protocol volumes for each case. The IOV of routine GTV-N was the most striking in all cases, with the smallest DSC of 0.37 (95% CI 0.32-0.42), followed by CTV, whereas GTV-T showed high consistency. After following the protocol, the smallest DSC of GTV-N was improved to 0.64 (95% CI 0.45-0.83, P = 0.005) but the DSC of GTV-T and CTV remained constant in most cases.

conclusionVariability in target volume delineation was observed, but it could be significantly reduced and controlled using mandatory interventions.

Indexed as

Observer VariationTumor BurdenChinaEsophageal NeoplasmsHumansOrgans at RiskPrognosisRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedThoracic NeoplasmsCancer of the esophagusInterobserver variabilityRadiation therapyTarget volume delineation

Identifiers

PMID34107984
PMCPMC8188796
OpenAlexW3167565342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.